Lyell leverages Werum PAS-X MES as a Service for clinical phase production

Case study

The US-based cell therapy biotech Lyell Immunopharma has successfully taken Werum PAS-X MES as a Service into operation at their GMP production site in Bothell, WA to produce autologous T cell cancer therapies.

Share

A woman in a white coat and mask interacts with a monitor, focused on the screen's content.

Results

1 cloud‑based MES platform deployed

Lyell implemented Werum PAS‑X MES as a Service on AWS, replacing manual paperwork and providing a secure, reliable foundation for clinical‑phase GMP production.

Multiple autologous therapies supported

The digital MES enabled scaling production across several cell therapy platforms with improved speed, efficiency, and compliance as operations grow.

0 manual errors in core processes

Digitization eliminated many manual steps and human error, boosting manufacturing efficiency, compliance, and data visibility for continuous improvement and faster time‑to‑market.

Unlock the full case study

Get the full details on the challenges and extraordinary outcomes. Download the complete case study.